
TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a review of 11 cohort studies.
Supplements and Featured Publications
over 26 years ago
Participating Facultyover 26 years ago
Introductionover 26 years ago
Underuse of Beta-Blockers in Cardiovascular Medicineover 26 years ago
Cardiodynamic Effects and Mechanisms of Action of Beta-Blockers





